A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Masitinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors AB Science
- 28 Jul 2018 The study has been discontinued in Spain.
- 25 May 2018 This trial has been Discontinued in Greece (End date: 2018-05-30).
- 15 Jun 2017 This trial has been suspended in Germany.